Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy

• Main Authors: N. N. Koloskova, E. A. Nikitina, V. M. Zakharevich, I. I. Muminov, V. S. Cvan, V. N. Poptsov, R. L. Ahmadzai, D. A. Izotov, A. O. Shevchenko
• Format: Article
• Language: Russian
• Published: Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov 2018-09-01
• Series: Vestnik Transplantologii i Iskusstvennyh Organov
• Subjects: heart transplantation; immunosuppressive therapy; nephrotoxicity of calcineurin inhibitor; renal dysfunction; еverolimus; mtor inhibitor
• Online Access: https://journal.transpl.ru/vtio/article/view/914

Heart transplantation is the «gold standard» of treatment severe heart failure. Patient survival after heart transplantation has improved dramatically since the  availability of calcineurin inhibitor (CNIs). However, nephrotoxicity of CNIs has been  largely responsible for the progressive development of renal dysfunction and  reduces long-term patient survival. Use mTOR inhibitor in immunosuppressive  therapy may improve renal function when everolimus is administered associated  with a progressive reduction of CNIs. The purpose of our report is to demonstrate  the successful case of conversion of the recipient after heart transplantation to  everolimus and to evaluate the effectiveness of this drug during the observation year after heart transplantation.